Rapid screening of HIV reverse transcriptase and integrase inhibitors

Area of Science:

• Virology
• Drug Discovery
• Cell Biology

Background:

• Approved anti-HIV drugs face challenges with toxicity and emerging drug resistance.
• There is a critical need for novel compounds effective against drug-resistant HIV-1 strains with improved safety profiles.

Purpose of the Study:

• To develop and validate an efficient assay for rapid screening of potential anti-HIV compounds.
• To simultaneously assess both cellular cytotoxicity and antiviral efficacy against wild-type (WT) and drug-resistant HIV-1 strains.

Main Methods:

• A 96-well plate assay was established involving target cell seeding and compound dilution.
• Antiviral efficacy was measured by luciferase reporter gene expression in cells infected with HIV-1 vectors (WT or drug-resistant).
• Cellular cytotoxicity was assessed using an ATP-dependent luminescence assay.

Main Results:

• The assay allows for rapid (4-day completion) and parallel screening of multiple compounds.
• Data are normalized to infectivity and ATP levels, providing accurate efficacy and toxicity measurements.
• The method is suitable for evaluating compounds against both WT and drug-resistant HIV-1 strains.

Conclusions:

• This screening technique offers a quick and accurate method for evaluating the efficacy and toxicity of novel anti-HIV drug candidates.
• The assay facilitates the identification of compounds with potential against drug-resistant HIV-1 strains and low cellular toxicity.
• This approach aids in the development of safer and more effective HIV therapies.